Genmab — December 2019
-
Gad vide hvad det er for et møde Keith Stewart har deltaget i, og som han formidler et slide fra i linket fra kl 9.20. Ifølge slidet ville 44% vælge D-RVd + asct til high risk pts. Det stemmer slet ikke med en tilsvarende afstemning på IMF-symposiet, al den stund D-RVd ikke er godkendt endnu og der kun foreligger data fra fase2 studiet Griffin, hvor der netop blev konkluderet at der ikke var fordel for HR-pts ved D-RVd. Der er noget, der ikke stemmer. Hør selv Peter Voorhees leder af Griffin:
-
-
Er der nogen kommentarer til TAK-079?
-
-
Razan Mohty
@razan_mohty
·
3 t
For all those who ask what’s next if we use big guns upfront in myeloma, Dr Lentzsch summarize TT options after 2nd and 3rd relapse. Lot’s of options still available: carfilzomib, POMA, elotuzumab, selinexor, Venetoclax. Add ADCs, BiTes and CAR-T #ASH19 #MMSM @ASH_hematologyhttps://twitter.com/razan_mohty/status/1203307029743443968 -
-
Thank you E L. I have a hard time keeping my tongue straight in the mouth with the many information we have today.
-
Jeg har set flere steder at TAK-079 og andre kaldes en ny lovende generation af CD38 midler. Hvad er er nyt?
-
ASH19 | What are the most promising CAR T therapies in development for MM? @ninashah33
shares her expert opinion live from Orlando -
-
Tak Bulder. Det sidste har jeg bemærket. Det med mindre dosis har jeg ikke tænkt over.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind